Search results
Results from the WOW.Com Content Network
Phencyclidine (PCP) is believed to be the first arylcyclohexylamine with recognized anesthetic properties, but several arylcyclohexylamines were described before PCP in the scientific literature, beginning with PCA (1-phenylcyclohexan-1-amine) the synthesis of which was first published in 1907. PCP itself was discovered in 1926 but not ...
3-MeO-PCP was first synthesized in 1979 to investigate the structure–activity relationships of phencyclidine (PCP) derivatives.The effects of 3-MeO-PCP in humans were not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCP was qualitatively similar to PCP with comparable potency. [1]
Phencyclidine or phenylcyclohexyl piperidine (PCP), also known in its use as a street drug as angel dust among other names, is a dissociative anesthetic mainly used recreationally for its significant mind-altering effects. [1] [4] PCP may cause hallucinations, distorted perceptions of sounds, and violent behavior.
This is an accepted version of this page This is the latest accepted revision, reviewed on 27 January 2025. The following is a list of mental disorders as defined at any point by the Diagnostic and Statistical Manual of Mental Disorders (DSM) or the International Classification of Diseases (ICD). A mental disorder, also known as a mental illness, mental health condition, or psychiatric ...
Phencyclidine, a high-affinity ligand of PCP site 2. PCP site 2 is a binding site that was identified as a high- affinity target for phencyclidine (PCP), an anesthetic and dissociative hallucinogen that acts primarily as an NMDA receptor antagonist . [ 1 ]
Phencyclidine, a hallucinogenic and dissociative recreational drug, also known as angel dust 3-HO-PCP, a designer drug related to phencyclidine; 3-MeO-PCP, a designer drug related to phencyclidine; 4-MeO-PCP, a research chemical related to phencyclidine; Pneumocystis pneumonia, a form of pneumonia caused by the yeast-like fungus Pneumocystis ...
The high affinity of 3-HO-PCP for opioid receptors is unique among arylcyclohexylamines and is in contrast to PCP, which has only very low affinity for the MOR (K i = 11,000–26,000 nM; 282- to 433-fold difference) and the other opioid receptors (K i = 4,100 nM for the KOR and 73,000 nM for the DOR).
This key finding allowed pharmacologists to begin researching if the Na V 1.7 is a substantial molecular target for analgesic (antipain) medications. [ 5 ] Sensitization , in the clinical sense of the word, is a phenomenon in which nociceptors in an area beyond a tissue injury exhibit decreased thresholds for activation.